# Documentation Gap Analysis: IXA-001 Hypertension Microsimulation

**Analysis Date:** February 2026
**Last Updated:** February 2026
**Purpose:** Identify documentation gaps and recommend additional reports for comprehensive model description

---

## Executive Summary

This analysis compares the existing documentation against the codebase modules to identify areas requiring additional documentation for HTA submission readiness and technical transparency.

### Documentation Completeness Score: 100% ✓

| Category | Status | Report Location |
|----------|--------|-----------------|
| Model Architecture | ✓ Complete | `microsimulation_technical_guide.md` |
| Simulation Process | ✓ Complete | `microsimulation_technical_guide.md` |
| Treatment Effects | ✓ Complete | `treatment_effects_and_phenotypes.md` |
| Risk Equations | ✓ **Complete** | `risk_equations_technical_report.md` |
| Cost Inputs | ✓ **Complete** | `cost_inputs_technical_report.md` |
| Utility Values | ✓ **Complete** | `utility_values_technical_report.md` |
| Validation | ✓ **Complete** | `model_validation_report.md` |
| PSA Parameters | ✓ **Complete** | `psa_parameters_technical_report.md` |
| Background Mortality | ✓ **Complete** | `background_mortality_technical_note.md` |
| Subgroup Analysis | ✓ **Complete** | `subgroup_analysis_methodology.md` |
| History Analyzer | ✓ **Complete** | `history_analyzer_technical_note.md` |

---

## Part 1: Complete Documentation Inventory

### Core Documentation

| Document | Location | Content | Status |
|----------|----------|---------|--------|
| **README.md** | `/README.md` | Model overview, installation, usage, results | ✓ Complete |
| **Microsimulation Technical Guide** | `/docs/microsimulation_technical_guide.md` | Simulation process, PSA, dual uncertainty | ✓ Complete |
| **Treatment Effects & Phenotypes** | `/docs/treatment_effects_and_phenotypes.md` | Treatment modifiers, efficacy coefficients | ✓ Complete |
| **Model Diagram Specification** | `/docs/Model_Diagram_Specification.md` | State transition diagrams, visual spec | ✓ Complete |
| **RFP Alignment Report** | `/docs/RFP_Alignment_Report.md` | RFP compliance, value proposition | ✓ Complete |
| **Project History** | `/reports/Project_History_and_Rationale.md` | Development phases, enhancement log | ✓ Complete |
| **Population Generator** | `/docs/Population_Generator_Presentation.md` | Population generation methodology | ✓ Complete |

### Technical Reports (Newly Completed)

| Document | Location | Content | Status |
|----------|----------|---------|--------|
| **Risk Equations Technical Report** | `/docs/risk_equations_technical_report.md` | PREVENT, KFRE, life tables, coefficients | ✓ Complete |
| **Cost Inputs Technical Report** | `/docs/cost_inputs_technical_report.md` | Drug costs, event costs, indirect costs, PSA | ✓ Complete |
| **Utility Values Technical Report** | `/docs/utility_values_technical_report.md` | EQ-5D values, disutilities, QALY calculation | ✓ Complete |
| **Model Validation Report** | `/docs/model_validation_report.md` | Face, internal, external, cross-validation | ✓ Complete |
| **PSA Parameters Compendium** | `/docs/psa_parameters_technical_report.md` | 47 parameters, distributions, correlations | ✓ Complete |
| **Subgroup Analysis Methodology** | `/docs/subgroup_analysis_methodology.md` | Etiology, phenotype, CKD subgroups | ✓ Complete |
| **Background Mortality Technical Note** | `/docs/background_mortality_technical_note.md` | Life tables, competing risks, validation | ✓ Complete |
| **History Analyzer Technical Note** | `/docs/history_analyzer_technical_note.md` | Trajectory analysis, dynamic risk modifiers | ✓ Complete |

### Code Modules - Documentation Status

| Module | File | Documentation |
|--------|------|---------------|
| **PREVENT Equations** | `src/risks/prevent.py` | ✓ `risk_equations_technical_report.md` |
| **KFRE Calculator** | `src/risks/kfre.py` | ✓ `risk_equations_technical_report.md` |
| **Life Tables** | `src/risks/life_tables.py` | ✓ `background_mortality_technical_note.md` |
| **Cost Module** | `src/costs/costs.py` | ✓ `cost_inputs_technical_report.md` |
| **Utilities Module** | `src/utilities.py` | ✓ `utility_values_technical_report.md` |
| **History Analyzer** | `src/history_analyzer.py` | ✓ `history_analyzer_technical_note.md` |
| **PSA Module** | `src/psa.py` | ✓ `psa_parameters_technical_report.md` |
| **Risk Assessment** | `src/risk_assessment.py` | ✓ `subgroup_analysis_methodology.md` |

---

## Part 2: Completed Reports Summary

### 2.1 Utility Values Technical Report ✓

**Status:** COMPLETE
**Location:** `/docs/utility_values_technical_report.md`
**CHEERS 2022 Compliance:** Items 12, 13, 14

**Contents:**
- Health state utility values by age/sex
- Utility decrements for MI, Stroke, HF, CKD stages, ESRD
- EQ-5D sources (Sullivan 2011, NICE DSU TSD 12)
- QALY calculation with half-cycle correction
- Beta distribution PSA parameters for all utilities

---

### 2.2 Model Validation Report ✓

**Status:** COMPLETE
**Location:** `/docs/model_validation_report.md`
**ISPOR-SMDM Compliance:** All 7 validation types

**Contents:**
- Face validity (expert review, conceptual model)
- Internal validity (76 unit tests, 100% pass rate)
- External validity (Framingham, ARIC, CKD-PC calibration)
- Cross-validation (ICER, NICE model comparison)
- Predictive validity framework

---

### 2.3 Risk Equations Technical Report ✓

**Status:** COMPLETE
**Location:** `/docs/risk_equations_technical_report.md`
**CHEERS 2022 Compliance:** Items 11, 18

**Contents:**
- AHA PREVENT equation coefficients (male/female)
- KFRE 4-variable model specification
- Life table sources (SSA 2021, ONS 2020-22)
- Probability conversion formulas
- Competing risks integration

---

### 2.4 Cost Inputs Technical Report ✓

**Status:** COMPLETE
**Location:** `/docs/cost_inputs_technical_report.md`
**CHEERS 2022 Compliance:** Items 15, 16, 17

**Contents:**
- Drug costs (IXA-001 $500/mo, Spironolactone $15/mo)
- Acute event costs (MI $25K, Stroke $15-22K, HF $18K)
- Chronic management costs (ESRD $90K/year)
- Indirect costs (human capital methodology)
- Gamma distribution PSA parameters

---

### 2.5 PSA Parameters Compendium ✓

**Status:** COMPLETE
**Location:** `/docs/psa_parameters_technical_report.md`
**CHEERS 2022 Compliance:** Items 20, 21

**Contents:**
- 47 parameter distributions with parameters
- Distribution selection rationale
- 4 correlation groups with matrices
- Cholesky decomposition implementation
- Convergence analysis (1,000 iterations recommended)

---

### 2.6 Background Mortality Technical Note ✓

**Status:** COMPLETE
**Location:** `/docs/background_mortality_technical_note.md`

**Contents:**
- US SSA 2021 and UK ONS 2020-22 life tables
- Annual to monthly probability conversion
- Linear interpolation methodology
- Competing risks framework
- Life expectancy validation

---

### 2.7 Subgroup Analysis Methodology ✓

**Status:** COMPLETE
**Location:** `/docs/subgroup_analysis_methodology.md`
**CHEERS 2022 Compliance:** Item 21

**Contents:**
- 5 subgroup dimensions, 17 categories
- Secondary HTN etiology (PA, RAS, Pheo, OSA, Essential)
- Age-based phenotypes (EOCRI, GCUA, KDIGO)
- Subgroup-specific risk and treatment modifiers
- ICEMAN credibility assessment

---

### 2.8 History Analyzer Technical Note ✓

**Status:** COMPLETE
**Location:** `/docs/history_analyzer_technical_note.md`

**Contents:**
- eGFR trajectory classification
- BP control quality grading
- Time-decay risk functions
- Comorbidity burden scoring (Charlson-based)
- Event clustering detection
- Adherence pattern analysis

---

## Part 3: Documentation Completion Matrix

### By Priority Level

```
                    HIGH IMPACT
                         │
    ┌────────────────────┼────────────────────┐
    │                    │                    │
    │  CRITICAL ✓        │    HIGH ✓          │
    │  • Utility Values  │    • Risk Equations│
    │  • Validation      │    • Cost Inputs   │
    │                    │                    │
URGENT ─────────────────────────────────────── CAN WAIT
    │                    │                    │
    │  MEDIUM ✓          │    LOW ✓           │
    │  • PSA Compendium  │    • History       │
    │  • Life Tables     │      Analyzer      │
    │  • Subgroup Methods│                    │
    │                    │                    │
    └────────────────────┼────────────────────┘
                         │
                    LOW IMPACT

              ALL REPORTS COMPLETE ✓
```

### Completion Timeline (Actual)

| Phase | Reports | Status |
|-------|---------|--------|
| **Phase 1** | Utility Values, Validation Report | ✓ Complete |
| **Phase 2** | Risk Equations, Cost Inputs | ✓ Complete |
| **Phase 3** | PSA Compendium, Subgroup Methods | ✓ Complete |
| **Phase 4** | Life Tables, History Analyzer | ✓ Complete |

---

## Part 4: CHEERS 2022 Compliance Mapping

| CHEERS Item | Status | Documentation |
|-------------|--------|---------------|
| 11. Analytic methods | ✓ Complete | `microsimulation_technical_guide.md` |
| 12. Measurement of outcomes | ✓ Complete | `utility_values_technical_report.md` |
| 13. Valuation of outcomes | ✓ Complete | `utility_values_technical_report.md` |
| 14. Valuation methods | ✓ Complete | `utility_values_technical_report.md` |
| 15. Resource estimation | ✓ Complete | `cost_inputs_technical_report.md` |
| 16. Unit costs | ✓ Complete | `cost_inputs_technical_report.md` |
| 17. Productivity costs | ✓ Complete | `cost_inputs_technical_report.md` |
| 18. Effect estimation | ✓ Complete | `risk_equations_technical_report.md` |
| 19. Uncertainty methods | ✓ Complete | `microsimulation_technical_guide.md` |
| 20. Uncertainty parameters | ✓ Complete | `psa_parameters_technical_report.md` |
| 21. Heterogeneity | ✓ Complete | `subgroup_analysis_methodology.md` |
| 22. Model validation | ✓ Complete | `model_validation_report.md` |

**CHEERS 2022 Compliance: 12/12 items (100%)**

---

## Part 5: Summary

### Completed Actions

1. **Utility Values Technical Report** ✓ COMPLETE
   - Health state utilities with EQ-5D sources
   - QALY calculation methodology documented

2. **Model Validation Report** ✓ COMPLETE
   - Face, internal, external validity documented
   - 76 unit tests, 100% pass rate

3. **Risk Equation Technical Report** ✓ COMPLETE
   - PREVENT and KFRE implementation documented
   - Coefficients verified against publications

4. **Cost Input Documentation** ✓ COMPLETE
   - All cost categories with sources
   - PSA distributions documented

5. **PSA Parameter Compendium** ✓ COMPLETE
   - 47 parameters with distributions
   - Correlation structure documented

6. **Background Mortality Technical Note** ✓ COMPLETE
   - Life table sources and methodology
   - Competing risks framework

7. **Subgroup Analysis Methodology** ✓ COMPLETE
   - 5 dimensions, 17 subgroup categories
   - Pre-specification and credibility assessment

8. **History Analyzer Technical Note** ✓ COMPLETE
   - Dynamic risk modification logic
   - Trajectory classification algorithms

---

## Appendix: Quick Reference - Documentation Map

| Topic | Primary Document | Code Reference |
|-------|------------------|----------------|
| Model Overview | `README.md` | - |
| Simulation Process | `microsimulation_technical_guide.md` | `src/simulation.py` |
| Treatment Effects | `treatment_effects_and_phenotypes.md` | `src/transitions.py` |
| Risk Equations | `risk_equations_technical_report.md` | `src/risks/prevent.py`, `src/risks/kfre.py` |
| Cost Inputs | `cost_inputs_technical_report.md` | `src/costs/costs.py` |
| Utility Values | `utility_values_technical_report.md` | `src/utilities.py` |
| Model Validation | `model_validation_report.md` | `tests/*.py` |
| PSA Parameters | `psa_parameters_technical_report.md` | `src/psa.py` |
| Background Mortality | `background_mortality_technical_note.md` | `src/risks/life_tables.py` |
| Subgroup Analysis | `subgroup_analysis_methodology.md` | `src/risk_assessment.py` |
| History Analysis | `history_analyzer_technical_note.md` | `src/history_analyzer.py` |

---

**Analysis Completed By:** HEOR Technical Documentation Team
**Original Analysis Date:** February 2026
**Documentation Completed:** February 2026
**Status:** ALL GAPS CLOSED - HTA SUBMISSION READY
